Advances in B-cell Precursor Acute Lymphoblastic Leukemia Genomics.

Area of Science:

• Pediatric Hematology Oncology
• Cancer Genomics
• Molecular Diagnostics

Background:

• Cytogenetic abnormalities are crucial for risk stratification in childhood B-cell precursor acute lymphoblastic leukemia (BCP-ALL).
• Established genetic markers like high hyperdiploidy and ETV6-RUNX1 fusion indicate good risk, while Philadelphia chromosome (Ph) positive ALL and KMT2A (MLL) gene rearrangements signify poor risk.
• A significant portion of BCP-ALL, termed B-other-ALL, lacked consistent molecular classification until recent studies.

Approach:

• Genomic screening and molecular profiling are employed to identify novel subgroups within BCP-ALL.
• Analysis focuses on identifying specific gene rearrangements and pathway activations, such as ABL-class tyrosine kinases, CRLF2/JAK-STAT signaling, IGH-DUX4, ZNF384, MEF2D, and PAX5.
• Investigating the therapeutic implications of these molecular alterations, including responses to tyrosine kinase inhibitors and JAK inhibitors.

Key Points:

• Ph-like/BCR-ABL1-like ALL, characterized by ABL-class tyrosine kinase rearrangements, shows poor response to chemotherapy but sensitivity to tyrosine kinase inhibitors.
• Deregulation of CRLF2 and JAK2 rearrangements activate the JAK-STAT pathway, suggesting a role for JAK inhibitors in treatment.
• Novel subgroups like IGH-DUX4 translocation (good outcome) and fusions involving ZNF384, MEF2D, and PAX5 amplification (poor outcome) are being defined.

Conclusions:

• Continued genetic screening is essential for the complete genomic classification of BCP-ALL.
• Identification of distinct molecular subgroups allows for the development of targeted therapies.
• This molecular stratification promises more effective and less toxic treatment strategies for pediatric BCP-ALL.